Thymine
Research stageRecent clinical, regulatory, research and industry developments relating to this drug.
Programmable DNA pyrimidine base editing via engineered uracil-DNA glycosylase.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- ESMO open1
- Nature communications1
- The New England journal of medicine1
- Akashi K1
- Amellal N1
- Baba E1
- Benhadji KA1
- Bondarenko I1
- Chang X1
- Ciardiello F1
- Cremolini C1
- Academy for Advanced Interdisciplinary Studies1
- Biomedical Pioneering Innovation Center1
- Changping Laboratory1
- Comprehensive Cancer Center1
- Graduate School of Medical Sciences1
- Kyushu University Hospital1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Thymine in the shared literature.
Studied across 3 of the same disease areas as Thymine in the shared literature.
Studied across 3 of the same disease areas as Thymine in the shared literature.
Studied across 3 of the same disease areas as Thymine in the shared literature.
Studied across 3 of the same disease areas as Thymine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature